DNA Sequencing Market Size and Forecast 2024-2033|Medable Inc., PathAI inc., Saama Technologies Inc., Apellis Pharmaceuticals Inc., TriNetX LLC

The DNA Sequencing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The DNA Sequencing Market:

https://www.thebusinessresearchcompany.com/report/dna-sequencing-global-market-report

According to The Business Research Company’s DNA Sequencing Global Market Report 2024, The dna sequencing market size has grown rapidly in recent years. It will grow from $11.84 billion in 2023 to $13.68 billion in 2024 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to human genome project, cost reduction, biomedical research expansion, clinical diagnostics adoption, pharmaceutical r&d needs.

The dna sequencing market size is expected to see rapid growth in the next few years. It will grow to $24.49 billion in 2028 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to next-generation sequencing (ngs) advancements, point-of-care sequencing, population genomics initiatives, ai and machine learning integration, precision medicine adoption. Major trends in the forecast period include single-cell sequencing advancements, epigenetics and transcriptomics focus, liquid biopsy development, ethical and privacy considerations, integration of nanotechnology.

The increasing prevalence of cancer is expected to propel the growth of the DNA sequencing market going forward. Cancer refers to uncontrolled cell growth, which impacts various organs and contributes to significant morbidity and mortality worldwide. DNA sequencing plays a crucial role in identifying genetic mutations, understanding tumor biology, and guiding treatment decisions, leading to improved outcomes in cancer care. For instance, in October 2022, Macmillan Cancer Support, the UK-based health care charity organization, there were 3 million people having cancer in 2020, and it is estimated that it will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the DNA sequencing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12604&type=smp

The dna sequencing market covered in this report is segmented –

1) By Product: Instruments, Consumables, Services

2) By Technology: Third Generation DNA Sequencing, Next-Generation Sequencing, Sanger Sequencing

3) By Application: Diagnostics, Biomarkers And Cancer, Reproductive Health, Personalized Medicine, Forensics, Other Applications

1) By End User: Hospitals And Healthcare Organizations, Academics And Research Institutions, Pharmaceutical And Biotechnology Companies, Other End Users

Advancements in single-cell DNA sequencing technologies are a key trend gaining popularity in the DNA sequencing market. Major companies operating in the DNA sequencing market are adopting new technologies to sustain their position in the market. For instance, in May 2023, Mission Bio Inc., a US-based biotechnology company, launched Tapestri v3, an advanced version of high-throughput single-cell DNA and multi-omics analysis platform. Tapestri v3 features breakthrough improvements in chemistry, significantly enhancing the detection of rare cells for various applications. With improved cell capture capabilities, researchers can now uncover deficient numbers of single cells that were previously undetectable, enabling a deeper understanding of the disease. This enhanced technology holds promise for applications like measurable residual disease (MRD) assessment in cancer, where Tapestri v3 enables the detection of relapse-driving clones that were previously missed. Additionally, it offers benefits for cell and gene therapy developers by enabling quality assessment at the single-cell level.

The dna sequencing market report table of contents includes:

1. Executive Summary

2. Artificial Intelligence (AI) In Clinical Trials Market Characteristics

3. Artificial Intelligence (AI) In Clinical Trials Market Trends And Strategies

4. Artificial Intelligence (AI) In Clinical Trials Market – Macro Economic Scenario

5. Global Artificial Intelligence (AI) In Clinical Trials Market Size and Growth

26. South America Artificial Intelligence (AI) In Clinical Trials Market

27. Brazil Artificial Intelligence (AI) In Clinical Trials Market

28. Middle East Artificial Intelligence (AI) In Clinical Trials Market

29. Africa Artificial Intelligence (AI) In Clinical Trials Market

30. Artificial Intelligence (AI) In Clinical Trials Market Competitive Landscape And Company Profiles

Top Major Players: